The Hyperinsulinemic Euglycemic Clamp (HIEC), originally developed by DeFronzo, is widely accepted as the “gold standard” for directly determining metabolic insulin sensitivity in humans.1 After an overnight fast, insulin is infused intravenously at a constant rate that may range from 5 to 120mU/m2/min (dose per body surface area per minute, during 180min). This constant insulin infusion results in a new steady-state insulin level that is above the fasting level (hyperinsulinemic). Consequently, glucose disposal in skeletal muscle and adipose tissue is increased while hepatic glucose production (HGP) is suppressed. Under these conditions, a glucose analyzer is used to frequently monitor blood glucose levels at 5–10min intervals, while 20% dextrose is given intravenously at a variable rate in order to “clamp” blood glucose concentrations in the normal range (euglycemic). After several hours of constant insulin infusion, steady-state conditions are typically achieved for plasma insulin, blood glucose, and the glucose infusion rate (GIR). Assuming that the hyperinsulinemic state is sufficient to completely suppress HGP, and since there is no net change in blood glucose concentrations under steady-state clamp conditions, the GIR must be equal to the glucose disposal rate (M). Thus, whole body glucose disposal at a given level of hyperinsulinemia can be directly determined. M is typically normalized to body weight or fat-free mass to generate an estimate of insulin sensitivity. Alternatively, an insulin sensitivity index (SI) derived from clamp data can be defined as SIClamp=MG×ΔI, where M is normalized for G (steady-state blood glucose concentration) and ΔI (difference between fasting and steady-state plasma insulin concentrations).2

The validity of glucose clamp measurements of insulin sensitivity depends on achieving steady-state conditions. “Steady-state” is often defined as a period greater than 30min (at least 1h after initiation of insulin infusion) during which the coefficients of variation for blood glucose, plasma insulin, and GIR are less than 5%.2 It is possible to use a radiolabeled glucose tracer under clamp conditions to estimate hepatic glucose production, so that appropriate corrections can be made to M in the event HGP is not completely suppressed.3–5 An alternative approach is to use an insulin infusion rate sufficiently high to completely suppress HGP according to the insulin sensitivity/resistance of the population to be studied.

M is routinely obtained at only a single insulin infusion rate, and therefore comparisons between M or SIClamp among different subjects is valid only if the same insulin infusion rate is used for all subjects.

The principal advantage of the glucose clamp in humans is that it directly measures whole body glucose disposal at a given level of insulinemia under steady-state conditions. Conceptually, the approach is straightforward but there is a limited number of assumptions that are clearly defined. In research settings where assessing insulin sensitivity/resistance is of primary interest and feasibility is not an issue, it is appropriate to use the glucose clamp technique.

The main limitations of the HIEC approach are that it is time-consuming, labor intensive, expensive, and requires an experienced operator to manage technical difficulties. Another limitation is that the clamp utilizes steady-state insulin levels that may be supraphysiological. This results in a reversal of the normal portal to peripheral insulin gradient. Thus, the glucose clamp may not accurately reflect insulin action and glucose dynamics under physiological conditions that a dynamic test, such as, an oral meal or oral glucose load may determine. Further, in the HIEC insulin sensitivity is measured only under a steady-state condition, and therefore, the test does not realistically portray dynamic conditions such as those occurring after normal meals. Because HIEC is dependent on steady-state conditions, insulin infusion is continuous for ≈3h, and the subjects are in the fasted state. The results of the HIEC may be limited by these restraints, because insulin release is pulsatile,6–8 and insulin action is sensitized in the postprandial state.9 Nevertheless, it should be remembered that the HIEC measures insulin-stimulated glucose disposal only at insulin levels in the upper physiological range; information on the effects of insulin on glucose uptake and production in the basal condition, which is physiologically very important, is not provided (unless tracers are used).10

The Insulin Tolerance Test (ITT) was one of the first methods developed to assess insulin sensitivity in vivo.11 In this method, a fixed bolus of regular insulin (0.1IU/kg bw) is given iv after an 8–10h fast. Blood samples are collected at 15 and 5min before and 3, 6, 9, 12, 15, 20 and 30min after insulin injection, and the plasma glucose decrement is then measured. Glucose is injected at 30min to stop the fall in plasma glucose.12,13 The faster the decline in glucose concentration, the more insulin sensitive the subject is. The slope of the linear decline in plasma glucose (KITT) can be calculated by dividing 0.693 by the plasma glucose half-time (50% from baseline):

The advantages of the ITT include its simplicity, rapidity and the use of a bolus injection of insulin. The bolus injection of insulin mimics the physiological pulsatile release of insulin.6 Furthermore, because glucose tolerance after a meal is dependent on insulin sensitivity, measuring insulin sensitivity in the prandial state is physiologically relevant.

Some of the drawbacks of this method include the supraphysiological insulin dose used, and also the fact that the test does not differentiate peripheral vs hepatic insulin resistance.14 Another major limitation of this test is the risk of hypoglycemia. Hypoglycemia triggers hormonal responses, which may interfere with insulin sensitivity and in turn slows the disappearance rate of glucose from plasma.15 In this view, the fall in plasma glucose concentration would be a function of the interplay between insulin, on the one hand, and glucagon, catecholamines, growth hormone and cortisol, on the other. Given that, the counterregulatory response occurs only 15–20min after insulin injection. The glucose fall occurring in the first 15min after iv insulin administration is probably a function of insulin-stimulated glucose uptake by tissues as well as insulin ability to suppress glucose output by the liver.16

A lower insulin dose method of 0.05YIU/kg bw, or shortening the test to 15min was suggested as an attempt to decrease the risk of hypoglycemia.14,17 The shorter version12,16 derived from the notion that the counterregulatory hormone response occurs only after 20min of the insulin infusion.18

The ITT has been shown to correlate with the HIEC in several studies.12,16 However, arterialization of blood is essential in the ITT, as data from standard venous blood measurements showed no significant relationship with HIEC-derived glucose disposal.16

In conclusion, the ITT should be used with great caution in insulin sensitive individuals because of the increased risk of hypoglycemia, even when the smaller dose version of the test is used. The shorter ITT is a valid test in large-scale studies, especially when the site of resistance is not of importance.

The insulin-suppression test (IST), another method that directly measures metabolic insulin sensitivity/resistance, was introduced by Shen et al. in 1970 and subsequently modified by Harano et al.19,20 After an overnight fast, somatostatin (250μg/h) or the somatostatin analog octreotide (25μg bolus, followed by 0.5μg/min)21 is intravenously infused, to suppress endogenous secretion of insulin and glucagon. Simultaneously, insulin (25mU/m2/min) and glucose (240mg/m2/min) are intravenously infused over 3h. Blood samples for glucose and insulin determinations are taken every 30min for 2.5h, and then at 10min intervals from 150 to 180min of the IST. The constant infusions of insulin and glucose determine steady-state plasma insulin (SSPI) and glucose (SSPG) concentrations. The steady-state period is assumed to be from 150 to 180min after initiation of the IST. SSPI concentrations are generally similar among subjects. Therefore, the SSPG concentration will be higher in insulin resistant subjects and lower in insulin sensitive subjects, i.e., SSPG values are inversely related to insulin sensitivity. The IST provides a direct measure (through SSPG) of the ability of exogenous insulin to mediate disposal of an iv glucose load, under steady-state conditions, where endogenous insulin secretion is suppressed.22

The SSPG is a highly reproducible direct measure of metabolic actions of insulin, that is, less labor intensive and less technically demanding than HIEC. Indeed, since there are no variable infusions with the IST, steady-state conditions are more easily achieved with the IST than with HIEC. In research settings, the IST can be used for larger populations that may pose difficulties for application of HIEC. ELIMINAR esta frase.

Many of the limitations of the IST are similar to those described for HIEC (with the exception that the IST is less technically demanding). Thus, it is impractical to apply the IST in large epidemiological studies or in the clinical care setting. SSPG under ideal conditions determines primarily skeletal muscle insulin sensitivity, and is not designed to reflect hepatic insulin sensitivity.22

The continuous infusion of glucose with model assessment (CIGMA) is a procedure that assesses insulin sensitivity through the evaluation of the near steady-state glucose and insulin concentrations after a continuous infusion of glucose, with model assessment.23 This method mimics postprandial glucose and insulin concentrations. CIGMA not only provides information about glucose tolerance and insulin sensitivity, but also about β-cell function. Using a mathematic model of glucose homeostasis, glucose and insulin values are compared with known physiologic data of glucose, and insulin kinetics in response to glucose infusion, which are derived from healthy lean subjects with no family history of diabetes.23

The glucose and insulin values used for CIGMA are obtained during the last 15min of the 60min continuous glucose infusion (5mg glucose/kg bw/min). Samples are collected at 5min intervals and the average is then compared with predicted values from the computer model. The median value for normal subjects is 1.35, and for diabetic patients with mild hyperglycemia is 4.0.23

There are two main advantages of CIGMA over Homeostasis Model Assessment (HOMA). First, the insulin values that are measured in CIGMA are much higher than those in HOMA owing to the glucose stimulus and second, higher insulin concentration in CIGMA stimulates peripheral glucose uptake producing a steady-state glucose concentration, which is a better reflection of the peripheral insulin sensitivity.18

Although CIGMA is more practical, cheaper and less invasive than the frequently sampled intravenous glucose tolerance test (FSIVGTT) and HIEC procedure, the model incorrectly assumes that levels of insulin resistance at the liver and peripheral tissues are equal. Furthermore, in insulin-deficient subjects, where the insulin response is insufficient to stimulate glucose uptake, the interpretation of CIGMA is difficult.

The minimal model, developed by Bergman, Cobelli and colleagues in 1979, provides an indirect measure of metabolic insulin sensitivity/resistance based on glucose and insulin data obtained during a frequently sampled intravenous glucose tolerance test (FSIVGTT).24 After an overnight fast, an intravenous bolus of glucose (0.3g/kg bw) is infused over 2min starting at time 0.

Currently, a modified FSIVGTT is used, where exogenous insulin (4mU/kg/min) is also infused over 5min beginning 20min after the iv glucose bolus.25,26 Some studies use tolbutamide (a potassium channel blocker) instead of insulin in the modified FSIVGTT, to stimulate endogenous insulin secretion.27,28

Blood samples are taken for plasma glucose and insulin measurements at different time points, before and 180min after glucose infusion. The data obtained are then subjected to minimal model analysis using the computer program MINMOD (minimal model approach – MINMOD), to generate an index of insulin sensitivity (SI).

The MINMOD is defined by two coupled differential equations with four model parameters (Fig. 1). The first equation describes plasma glucose dynamics in a single compartment. The second equation describes insulin dynamics in a “remote compartment”. The structure of the MINMOD allows it to uniquely identify model parameters, which determine a best fit to glucose disappearance during the modified FSIVGTT. SI is calculated from two of these model parameters, and is defined as fractional glucose disappearance per insulin concentration unit.29

Fig. 1.

Schematic equations and parameters for the minimal model of glucose metabolism. Differential equations describing glucose dynamics [G(t)] in a monocompartmental “glucose space” and insulin dynamics in a “remote compartment” [X(t)] are shown at the top. Glucose leaves or enters its space at a rate proportional to the difference between plasma glucose level, G(t) and the basal fasting level, Gb. In addition, glucose also disappears from its compartment at a rate proportional to insulin levels in the “remote” compartment [X(t)]. In this model, t – time; G(t) – plasma glucose at time t; I(t) – plasma insulin concentration at time t; X(t) – insulin concentration in “remote” compartment at time t; Gb – basal plasma glucose concentration; Ib – basal plasma insulin concentration; G(0) – G0 (assuming instantaneous mixing of the iv glucose load); p1, p2, p3 and G0 – unknown parameters in the model that are uniquely identifiable from FSIVGTT; glucose effectiveness (SG) – p1 and insulin sensitivity – p3/p2.

(0.07MB).

Adapted from Ref. 29.

In addition to SI, other minimal model parameters may be used to estimate a “glucose effectiveness” index (SG). SG is defined as the ability of glucose per se to promote its own disposal and inhibit hepatic glucose production (HGP) in the absence of an incremental insulin effect (i.e., when insulin is at basal levels).

Minimal model analysis of the modified FSIVGTT is easier than HIEC method because it is slightly less labor intensive, steady-state conditions are not required, and there are no iv infusions that require constant adjustment. Unlike HIEC or IST, information about insulin sensitivity, glucose effectiveness, and β-cell function can be derived from a single dynamic test. The minimal model generates excellent predictions of glucose disappearance during the FSIVGTT.

In research settings, where assessing insulin sensitivity along with glucose effectiveness and β-cell function is of interest, minimal model analysis of the insulin-modified FSIVGTT may be appropriate. The minimal model approach is simpler than direct methods for determining insulin sensitivity. Nevertheless, it still involves iv infusions with multiple blood sampling over a 3h period, that is, nearly as labor intensive as the HIEC or IST. In addition, many limitations of minimal model analysis stem from the fact that the model oversimplifies the physiology of glucose homeostasis.29

Another oversimplification of the minimal model involves lumping together effects of insulin to promote peripheral glucose utilization and suppress HGP. As insulin sensitivity/resistance varies, the relative contribution of HGP to SI may vary significantly. Since the minimal model relies on a dynamic test to evaluate insulin sensitivity, estimates of SI are much less reliable in individuals with impaired insulin secretion and/or significant insulin resistance (when compared with healthy subjects). Under these conditions, the minimal model may overestimate SG to accurately predict the disappearance of glucose during the FSIVGTT. Indeed, estimates of SG are spuriously affected by differences in insulin secretory capacity.26,30 Moreover, for similar reasons, minimal model analysis often generates senseless negative values for SI in a substantial proportion of subjects with diabetes, who have minimal insulin secretory capacity and significant insulin resistance.2,30 These nonsystematic errors inherent in the minimal model approach are highlighted by calibration model analysis, demonstrating that some simple surrogate indexes of insulin sensitivity have better absolute accuracy for predicting SIClamp than the minimal model-derived SI.31

The Oral Glucose Tolerance Test (OGTT) is a simple test, widely used in clinical practice to diagnose glucose intolerance and type 2 diabetes.18,32,33 After an overnight fast, blood samples for determinations of glucose and insulin concentrations are taken at 0, 30, 60, and 120min following a standard oral glucose load (75g).33 A diagnosis of diabetes is conferred if an individual has a plasma glucose level ≥200mg/dl (11Ymmol/l) as measured 2h after the ingestion of a 75g glucose load. If an individual has a value in the range of 140–199mg/dl (7.7–11Ymmol/l) 2h post-glucose load, it is designated as having impaired glucose tolerance.33 Oral glucose tolerance reflects the efficiency with which the body handles glucose after an oral glucose load.

The OGTT mimics the glucose and insulin dynamics of physiological conditions more closely than conditions of the HIEC, IST or frequently sample intravenous glucose tolerance test (FSIVGTT).34 However, it is important to recognize that glucose tolerance and insulin sensitivity are not equivalent concepts. In addition to metabolic actions of insulin, insulin secretion, incretin effects, and other factors contribute importantly to glucose tolerance. Thus, the OGTT, by itself, provides useful information about glucose tolerance but not insulin sensitivity/resistance per se.35,36 During the OGTT, the use of a glucose tracer and both insulin and C-peptide plasma measurements at specific time points, allows the calculation of glucose clearance.

The OGTT is technically quite simple to perform and certainly lower in cost than HIEC or FSIVGTT. These considerations have made the OGTT the glucose challenge test of choice in clinical situations.37 However, there are some problems with the OGTT that make it less desirable for use in research situations. First, there is variability in the rate of gastric emptying and glucose absorption from the gastrointestinal tract, causing some imprecision from the start. This variability can partially account for poorly reproducible results even within the same individual.38 Second, glucose measurements in the standard OGTT do not give adequate information regarding the dynamics of glucose and insulin action.33

The OGTT is a relatively crude measure of glucose tolerance. It does not measure the components of insulin sensitivity and insulin secretion. In light of this limitation, attempts have been made to obtain indices from OGTT data that might better reflect β-cell function and insulin sensitivity.39,40

In an attempt to study the ability to regulate blood glucose in a more physiological situation than the OGTT, some authors measure the glycemic profile in response to the ingestion of a mixed meal containing carbohydrates, fat and proteins; the Meal Tolerance Test (MTT).

The experimental procedure for the MTT is similar to the OGTT, that is, after an overnight fast (10–12h), a mixed meal (liquid or solid) is given and the glycemic profile is measured throughout 2h; usually the insulin profile is also determined during the same period of time.34,36

The MTT is a “physiologic” variant of OGTT41 offering several advantages: (a) lack of artifactual postload hypoglycemia, thus making this test suitable for the study of postprandial hypoglycemia, a situation which is frequently due to high values of insulin sensitivity, but also to hyperinsulinism in a context of insulin resistance42; (b) use of a physiologic stimulus triggering a cephalic phase proportional to palatability scores43; (c) possibility to measure insulin sensitivity with a modified algorithm based on the minimal model36 as well as glucose effectiveness and insulin secretion; (d) potential for evaluating the physiologic effects of incretins.44

The MTT can represent a simple procedure, less unpleasant for the patient than the standard OGTT, and providing both a physiologic picture of glucoregulation, and a sophisticated and precise analysis of this glucoregulation, in terms of insulin sensitivity, glucose effectiveness, and insulin secretion.41

The β-cell response is stronger after a mixed meal than after an OGTT with equal carbohydrate quantity, both for classical and model-based parameters. The higher response was mostly explained by higher β-cell sensitivity during the meal, which may lead to lower glucose excursions.45

Several factors may contribute to differences in insulin secretion following an MTT compared with the OGTT. The MTT has a lower glycemic index than the OGTT, which may lead to lower glucose excursions.46 Moreover, slower gastric emptying following the MTT due to larger volume,47 solid character,48 and fat content49 will lead to a slower entry of nutrients into the circulation.

The MTT might be considered as an additional tool for the assessment of metabolic abnormalities, in glucose-intolerant and insulin-resistant states.34

Thus, the MTT is a more physiological test than the OGTT, in regard to human diet, and is potentially able to give useful information concerning islet β-cell function in the different categories of glucose intolerance,50 but not insulin sensitivity/resistance per se.36

As any other method that measures glucose tolerance, the MTT does not assess insulin sensitivity directly and may not be repeated in the same subject or animal on the same day.

A new method for insulin sensitivity quantification, called the Rapid Insulin Sensitivity Test (RIST), was described and evaluated for use in rats,51,52 cats53,54 mice55 and humans.56 The standard dynamic profile for the RIST in fed and fasted humans as well as the RIST insulin sensitivity index is shown in Fig. 2.

Fig. 2.

(A) Mean profile using the dynamic analysis of the pattern of glucose infusion during the Rapid Insulin Sensitivity Test (RIST). The mean RIST curves were obtained by averaging glucose infusion rates at 0.1-min intervals throughout the test (Postprandial RIST (bold line) and the RIST obtained after 24h-fast (simple line)). (B) Calculation of the area under the curve during the 24 h-fast and postprandial RIST, that corresponds to the total amount of glucose infused to maintain euglycemia over the test period, which is terminated when no further glucose infusion is required (RIST index).56

(0.09MB).

The RIST is an euglycemic test and is carried out after establishing the glycemic baseline, which is done by taking arterialized venous blood samples at 5min intervals until three consecutive measurements are stable. An insulin infusion is commenced (50YmIU/kg administered over 5min) and, after 1min, glucose samples are taken at 2min intervals, and glucose is infused intravenously at a variable rate to maintain euglycemia. The test is completed when no more glucose is required. At the standard test dose of insulin of 50YmIU/kg, the RIST in the fasted state is complete within approximately 40min. The RIST index, the insulin sensitivity parameter, is simply the amount of glucose that had to be administered in order to maintain euglycemia after the bolus administration of insulin.52

The majority of the insulin sensitivity tests are done in the fasted state, when insulin sensitivity would be logically anticipated to be at its lowest level. Studies performed by Patarrão et al. and Lautt et al. indicated that the fasted state results in a very low insulin responsiveness. It is reasonable that insulin sensitivity should be under a regulatory mechanism such that in the fasted state insulin effect would be minimized, and inappropriate release of insulin would not, therefore, lead to life-threatening hypoglycemia. The RIST can be carried out in the fed state.9,56 Furthermore, the RIST allows insulin sensitivity assessment before and after a meal, making it possible to test both meal and drug effects on insulin sensitivity.56,57

The RIST is extremely sensitive and can be shown to generate dose-response relationships to insulin, which makes the RIST the most advantageous method in the determination of small differences in insulin sensitivity. This method is able to be carried out more than one time in the same subject with high reproducibility, and is sufficiently versatile to permit paired experimental designs, in the same subjects and on the same day. Both the accuracy and precision of the test can be assessed from determination of the deviation from the ideal euglycemic target.52

Insulin release normally occurs in a pulsatile manner, and hormones released in a pulsatile manner are best studied by pulsatile administration.58 Based on this assumption, the intravenous insulin bolus administered at the beginning of the RIST mimics the physiological insulin action. It also avoids the vagal withdrawal and sympathetic activation induced by sustained hyperinsulinemia, during the HIEC55,59 and the hypoglycemia caused by the acute ITT.59 It does not alter levels of counter-regulatory hormones, such as catecholamines, somatostatin or glucagon.54 Moreover, both insulinemia and glycemia return to basal levels after each RIST.

One methodological issue relates to the basal glucose concentration determined before and after the RIST. Previous studies demonstrate clearly that there is no mean change in basal blood glucose levels used as the euglycemic target when, for example, compared before and after denervation of the hepatic plexus in rats60 or atropine.61 In addition, we have also determined that there is no correlation between the magnitude of the RIST index and basal glucose levels when compared using a large number of data points.52 Of more concern is the importance that glucose uptake or output should not change during the RIST. Whatever stimulus is used, including either ablation or stimulation protocols, the stimulus is administered prior to conducting the RIST, and a new stable glycemic baseline must be demonstrated. In addition, at the conclusion of the RIST index, the re-established baseline must not be significantly altered. In the event that such alteration occurs, it suggests that glucose output either increased or decreased during the test. This is usually obvious by comparing the shape of normal RIST curves with that obtained in the presence of the altered baseline. In such situations, the data must be excluded, and the RIST repeated.

None of the available methods available to estimate insulin sensitivity/resistance proved to be a reliable way to assess insulin sensitivity/resistance since most of them have non-physiological continuous infusion of insulin and/or glucose, which interfere with peripheral insulin sensitivity/resistance; take a long time to be performed; could not avoid counter-regulatory responses to the hypoglycemia that follows an insulin bolus; could not allow the assessment of insulin sensitivity in different conditions in the same subject, and in the same day; and they only evaluate insulin sensitivity/resistance in the fasted state. Based on all of these drawbacks, it was necessary to develop another method for assessing insulin sensitivity/resistance.

To summarize, the RIST is a quick method to evaluate insulin sensitivity, reproducible in the same subject and on the same day, utilizes a bolus of insulin to mimic pulsatile insulin release, and can be performed in the fed or fasting state. In addition, since the RIST is an euglycemic test, avoids hypoglycemia and prevents the activation of counter-regulatory hormones. The RIST provides a new powerful tool to dissect insulin action in the fasted and fed state, and may provide a means to detect the pre-diabetic state, where early insulin resistance can be detected well before the impairment of the direct effect of insulin at a time when lifestyle interventions can be readily tested.

The Homeostasis Model Assessment (HOMA), developed in 1985, is a model of interactions between glucose and insulin dynamics, that is then used to predict fasting steady-state glucose and insulin concentrations, for a wide range of possible combinations of insulin resistance and β-cell function.62 The model assumes a feedback loop between the liver and β-cell62,63; and glucose concentrations are regulated by insulin-dependent hepatic glucose production, while insulin levels depend on the pancreatic β-cell response to glucose concentrations. Thus, a diminished response to glucose-stimulated insulin secretion reflects deficient β-cell function. Likewise, insulin resistance is reflected by diminished suppressive effect of insulin on hepatic glucose production.

HOMA model describes this glucose-insulin homeostasis by a set of empirically derived non-linear equations. The model predicts fasting steady-state levels of plasma glucose and insulin for any given combination of pancreatic β-cell function (HOMA%B) and insulin sensitivity (HOMA%S).

In practical terms, most studies using HOMA employ an approximation described by a simple equation to determine a surrogate index of insulin resistance. This is defined by the product of the fasting glucose and fasting insulin, divided by a constant. The formula for the HOMA model is:

The denominator of 22.5 is a normalizing factor, i.e., the product of normal fasting plasma insulin of 5μIU/ml and normal fasting plasma glucose of 4.5Ymmol/l obtained from an “ideal and normal” individual.62 Therefore, for an individual with normal insulin sensitivity, HOMA=1. It is important to note that, over wide ranges of insulin sensitivity/resistance, log (HOMA) transforms the skewed distribution of fasting insulin values to determine a much stronger linear correlation with HIEC estimates of insulin sensitivity.2

HOMA or log (HOMA) is extensively used in large epidemiological studies, prospective clinical trials, and research studies. In research settings where assessing insulin sensitivity/resistance is of secondary interest or feasibility issues preclude the use of direct measures by HIEC, it may be appropriate to use log (HOMA).63

Quantitative insulin sensitivity check index (QUICKI) is an empirically derived mathematical transformation that uses fasting blood glucose and plasma insulin concentrations. It provides a reliable, reproducible, and accurate index of insulin sensitivity with excellent positive predictive power.2,64 Since fasting insulin levels have a non-normal skewed distribution, log transformation improves its linear correlation with reference standard glucose clamp (SIClamp). However, as with 1/(fasting insulin) and the glucose/insulin ratio, this correlation is not maintained in diabetic subjects with fasting hyperglycemia and impaired β-cell function that is insufficient to maintain euglycemia. To accommodate these clinically important circumstances where fasting glucose is inappropriately high, insulin is inappropriately low, application of logarithm to both fasting glucose, and fasting insulin provides a reasonable correction such that the linear correlation with SIClamp is maintained, in both diabetic and non-diabetic subjects. The reciprocal of this sum results in further transformation of the data generating an insulin sensitivity index that has a positive correlation with SIClamp. Thus, QUICKI is defined by the following formula:

QUICKI is among the most thoroughly evaluated and validated surrogate index for insulin sensitivity. As a simple, useful, inexpensive, and minimally invasive surrogate for HIEC-derived measures of insulin sensitivity, QUICKI is appropriate and effective for use in large epidemiological or clinical research studies, to follow changes after therapeutic interventions, and for use in studies where evaluation of insulin sensitivity is not of primary interest.2,65

QUICKI and HOMA were derived in a completely different conceptual fashion. Nevertheless, these two surrogate indexes are mathematically related, i.e., QUICKI is proportional to 1/log (HOMA).

The major advantage of both the QUICKI and HOMA models is that they both require only one blood draw from a fasting patient. They thus do not require extensive technical expertise, and constitute a much lower cost per subject when compared with the HIEC or the FSIVGTT, making the QUICKI and HOMA models much more practical for use in large-scale epidemiologic studies, and for clinical situations.63

However, the major disadvantage is that both of these methods fail to provide information about the stimulated glucose and insulin systems. Essentially, they provide information only about what is occurring with homeostatic mechanisms in the fasting state, largely reflecting insulin's effect on hepatic glucose production and not on peripheral glucose uptake, which is the more relevant aspect concerning insulin action/resistance.